

AMARIN CORP PLC\UK  
Form 8-K  
June 19, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): June 19, 2013**

**Amarin Corporation plc**

**(Exact name of registrant as specified in its charter)**

**England and Wales**  
**(State or other jurisdiction**  
  
**of incorporation)**

**000-21392**  
**(Commission**  
  
**File Number)**

**Not applicable**  
**(I.R.S. Employer**  
**Identification No.)**

Edgar Filing: AMARIN CORP PLC\UK - Form 8-K

**2 Pembroke House, Upper Pembroke Street 28-32, Dublin 2,  
Ireland**

(Address of principal executive offices)

**Not applicable**

(Zip Code)

**Registrant's telephone number, including area code: +353 1 6699 020**

**Not Applicable**

**Former name or former address, if changed since last report**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On June 19, 2013, Amarin Corporation plc (Amarin) issued a press release titled "Amarin Informed by FDA of October 16 Advisory Committee Decision in Connection with Supplemental New Drug Application (sNDA) for Vascepa<sup>(R)</sup> in the Treatment of Patients with High Triglycerides ( $\geq 200$  mg/dL and  $< 500$  mg/dL) with Mixed Dyslipidemia." A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

Exhibit

| No.  | Description                        |
|------|------------------------------------|
| 99.1 | Press Release, dated June 19, 2013 |

\* \* \*

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 19, 2013

**Amarin Corporation plc**

By: /s/ John Thero  
John Thero  
President

**Exhibit Index**

Exhibit

| No.  | Description                        |
|------|------------------------------------|
| 99.1 | Press Release, dated June 19, 2013 |